Catherine Pickering, iOnctura CEO
June 20, 2024 02:03 AM EDTUpdated 08:37 AM
Financing
R&D

iOnc­tura rais­es €80M to ad­vance ear­ly-stage rare eye can­cer treat­ment

Ayisha Sharma

News Reporter

iOnc­tura has col­lect­ed €80 mil­lion ($85.9 mil­lion) in a Se­ries B round to sup­port its lead can­cer can­di­date through a Phase 2 test in uveal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times